glur 6

GluR6 antagonist-1 inhibits the pY binding site of tyrosine kinase p56lck SH2 domain.

TAT-GluR6-9c is a blocker of GluR6-PSD95 interaction. It inhibits JNK activation and c-Jun phosphorylation by regulating GluR6-mediated signaling pathways, thereby reducing Fas L expression and decreasing apoptosis. TAT-GluR6-9c is applicable in the study of cerebral ischemia and neuroprotection strategies.

DCG-IV is an effective agonist of class II mGluR. DCG-IV has anticonvulsant and neuroprotective effects. The EC50 of mGlu2R and mGlu3R are 0.35 and 0.09 μM, respectively. DCG-IV is also a competitive antagonist of Group I (IC50: mGlu1 / 5R = 389/630 μM) a

L-Cysteinesulfinic acid is an endogenous neurotransmitter with agonistic effects on a variety of metabotropic glutamate receptors (mGluRs), including mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, with a pEC50 = 2.7 to 4.0. L- Cysteinesulfinic acid is a pld-coupled agonist of metabotropic excitatory amino acid (EAA) receptors.

(RS)-PPG is a potent and selective group III mGluRs agonist (EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively), with neuroprotective and anticonvulsive activity.

L-Cysteinesulfinic acid monohydrate is a potent agonist at rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively [1].